Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements

Alberto Piubello, Mahamadou Bassirou Souleymane, Souleymane Hassane-Harouna, Abdourahamane Yacouba, Pauline Lempens, Mourtala Mohamed Assao-Neino, Ibrahim Maman-Lawan, Sala Attaher, Boubacar Moustapha, Alphazazi Soumana, Assiatou Gagara-Issoufou, Nimer Ortuno-Gutierrez, Alberto Roggi, Mourad Gumusboga, Zelika Hamidou-Harouna, Jeroen Dockx, Saidou Mamadou, Bouke C. de Jong, Tom Decroo, Armand Van Deun

Research output: Contribution to journalA1: Web of Science-article

2 Downloads (Pure)

Abstract

Background: In Niger, the Shorter Treatment Regimen (STR) has been implemented nationwide for rifampicin resistant tuberculosis (RR-TB), since 2008. No previous publication has shown the results from countrywide programmatic implementation using few exclusion criteria, nor exhaustively assessed the effect of initial resistance to companion drugs on outcomes.

Methods: The National Tuberculosis Programme and the Damien Foundation conducted a retrospective observational study to evaluate the management of RR-TB from 2008 to 2016. Baseline resistance to drugs was assessed phenotypically, complemented by screening the inhA, katG and pncA genes. Cured patients were followed-up for a period of one year after cure.

Findings: Among 1044 patients tested for rifampicin resistance, mainly previously treated patients, 332 were diagnosed with pulmonary RR/TB, 288 were enrolled on treatment and 255 started on STR. Six patients received a modified STR.

Among 249 patients on standardised STR, 207 (83.1%) were cured relapse-free, eight (3.2%) had failure, 23 (9.2%) died, seven (2.8%) were lost to follow-up and four (1.6%) relapsed.

The risk of unfavourable outcome was higher in patients with initial resistance to fluoroquinolones (aOR 20.4, 95%CI:5.6-74.6) and very severely underweight (aOR 3.9, 95%CI:1.5-10.1). Successful outcome was not affected by initial resistance to companion drugs. Serious ototoxicity was reported in eight patients (3.2%).

Interpretation: A comprehensive nationwide approach to multidrug-resistant tuberculosis management using the STR was feasible and successful. Outcomes were not affected by initial resistance to companion drugs. Our study confirms the effectiveness and safety of the STR.

Original languageEnglish
Article number105844
JournalRespiratory Medicine
Volume161
Number of pages9
ISSN0954-6111
DOIs
Publication statusPublished - 2020

Keywords

  • Multidrug-resistant tuberculosis
  • Shorter treatment regimen
  • Niger
  • MYCOBACTERIUM-TUBERCULOSIS
  • ETHIONAMIDE

Cite this